POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)

Inclusion Criteria: * Patient has distal unprotected Left-Main coronary artery (ULMCA) disease with angiographic diameter stenosis (DS) ≥50% requiring revascularization. * Left-Main Medina classification 100, 110, 101, 011, 010, 111 * Clinical and anatomic eligibility for PCI as agreed by the local Heart Team including anatomic SYNTAX Score (\<33). * Distal left main reference vessel diameter ≥3.0 mm and ≤5.5 mm. All target lesions must be located in a native coronary artery. * Patient with silent ischemia, chronic stable angina or stabilized acute coronary syndromes with normal cardiac biomarker values * Able to understand and provide informed consent and comply with all study procedures including follow-up Exclusion Criteria: * Prior PCI of the left main bifurcation at any time prior to enrollment * Currently participating in another trial and not yet at its primary endpoint. * Prior PCI of any other (non left main bifurcation) coronary artery lesion within 6 months (\<6 months) prior to enrollment. * Left-Main Medina classification 001. * Any segment of the left main bifurcation (distal left main, ostial Left Anterior Descending Artery (LAD) or ostial Left Circumflex Artery (LCX) presenting with a chronic total occlusion, or containing a visible thrombus. * Excessive angulation of the left main bifurcation (i.e. an angulation \>90° between proximal LAD and proximal LCX) * Direct stenting of the left main bifurcation * Prior Coronary Artery Bypass Surgery (CABG) at any time prior to enrollment * Patient requiring or may require additional surgery (cardiac or non-cardiac) within one year * Ongoing myocardial infarction or recent myocardial infarction with cardiac biomarker levels still elevated. * Known renal insufficiency (e.g. serum creatinine \>2.5mg/dL, or creatinine clearance ≤30mL/min, or patient on dialysis). * Known contraindication or hypersensitivity to sirolimus, everolimus, cobalt-chromium, or to medications such as aspirin, heparin, bivalirudin, and all of the following four medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor. * Patients unable to tolerate, obtain or comply with dual antiplatelet therapy for at least 12 months. * Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential). * Concurrent medical condition with a life expectancy of less than 12 months. * The patient is unwilling/not able to return for outpatient clinic at 12 month follow-up. * Currently participating in another trial and not yet at its primary endpoint.